Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory, or atrophic endometrium · endometrial hyperplasia
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes regression of endometrial hyperplasia (with or without atypia) to… compared with levonorgestrel intrauterine system (very low certainty).
1 finding from 1 review
Recurrence of endometrial hyperplasia · endometrial hyperplasia
The review found no eligible studies for this question.
1 finding from 1 review
Progression of endometrial hyperplasia to endometrial cancer · endometrial hyperplasia
1 finding from 1 review
Hysterectomy rate · endometrial hyperplasia
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes hysterectomy rate compared with levonorgestrel intrauterine system (very low certainty).
1 finding from 1 review
Abnormal uterine bleeding · endometrial hyperplasia
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes abnormal uterine bleeding compared with levonorgestrel intrauterine system (very low certainty).
1 finding from 1 review
Adverse effects during treatment ‐ all effects · endometrial hyperplasia
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes adverse effects during treatment ‐ all effects compared with levonorgestrel intrauterine system (very low certainty).
1 finding from 1 review
Adverse events: nausea · endometrial hyperplasia
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes adverse effects during treatment ‐ nausea compared with levonorgestrel intrauterine system (very low certainty).
1 finding from 1 review
Adverse effects during treatment ‐ heaviness in lower abdomen · endometrial hyperplasia
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes adverse effects during treatment ‐ heaviness in lower abdomen compared with levonorgestrel intrauterine system (very low certainty).
1 finding from 1 review
Adverse effects during treatment ‐ pain in abdomen · endometrial hyperplasia
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes adverse effects during treatment ‐ pain in abdomen compared with levonorgestrel intrauterine system (very low certainty).
1 finding from 1 review
Uterine fibroid‐related symptoms (abnormal uterine bleeding, measured at 12 weeks, with the pictorial blood assessment chart (PBAC); lower = better) · women with uterine fibroids
2 findings from 1 review
Adverse events (spotting at 3 and 6 months) · women with uterine fibroids
1 finding from 1 review
Haemoglobin level ‐ Haemoglobin level at 12 months Scale from: 0 to 20. · women with uterine fibroids
1 finding from 1 review
Fibroid size · women with uterine fibroids
1 finding from 1 review
Adverse events · women with uterine fibroids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in fibroid related symptoms · women with uterine fibroids
1 finding from 1 review
Change in haemoglobin level from baseline · women with uterine fibroids
2 findings from 1 review
Fibroid size · women with uterine fibroids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Regression rate at 6 months · women with atypical endometrial hyperplasia
It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes regression rate at 6 months compared with medroxyprogesterone (MPA) 10 mg (very low certainty).
1 finding from 1 review
Nausea · women with atypical endometrial hyperplasia
It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes nausea over 6‐month compared with medroxyprogesterone (MPA) 10 mg (very low certainty).
1 finding from 1 review
Vaginal bleeding over 6‐month · women with atypical endometrial hyperplasia
Levonorgestrel‐releasing intrauterine system (LNG‐IUS) may leads to higher vaginal bleeding over 6‐month compared with medroxyprogesterone (MPA) 10 mg (low certainty).
1 finding from 1 review